INM

Innovative New Media and Tree3 Partner to Advance NIL Collective Marketing

Retrieved on: 
Tuesday, October 3, 2023
New media, INM, Music, Partnership, Food, Historically black colleges and universities, The Icon, HBCU, NIL, Athlete, Rutgers University, Grambling State University, Software, Video game, Online shopping, Sport

MIAMI, Oct. 3, 2023 /PRNewswire/ -- Innovative New Media (INM), a strategic marketing company transforming the NIL industry, is excited to announce their partnership with Tree3 .

Key Points: 
  • MIAMI, Oct. 3, 2023 /PRNewswire/ -- Innovative New Media (INM), a strategic marketing company transforming the NIL industry, is excited to announce their partnership with Tree3 .
  • "Tree3 is excited to partner with INM to bring marketplace functionality to NIL collectives," said Matt Leinart of Tree3.
  • Innovative New Media complements the work of Tree3 by making it possible for these products to be marketed by athletes and by driving more traffic to the storefront.
  • "Our team at Knight Society is excited to be working with Innovative New Media and Tree3," said Knight Society's founder and CEO Geo Baker.

Innovative New Media Announces Four More NIL Collective Launches

Retrieved on: 
Wednesday, September 20, 2023
New media, INM, University, Marketing, University of Florida, NIL, Athlete, Rutgers University, Grambling State University, Florida State Seminoles, Battle, Campuses of the University of Georgia, Ohio State University, Social media, Sport

MIAMI, Sept. 20, 2023 /PRNewswire/ -- Innovative New Media (INM), a strategic marketing company, has announced four new partnerships with collectives to produce additional funding for athletes through endorsement opportunities, bridging the gap between athletes and brands. Among these partnerships are: Florida Victorious, The Battle's End, Knight Society, and The Icon 1901.

Key Points: 
  • Among these partnerships are: Florida Victorious, The Battle's End, Knight Society, and The Icon 1901.
  • "We continue to increase our reach in the NIL space and are excited to provide these opportunities to the collectives and athletes.
  • INM creates the opportunity for athletes to connect with the marketing of brands allowing for the monetization of their content.
  • Based in Miami, FL, Innovative New Media is a strategic marketing company focusing on NIL opportunities by bringing together brands, collectives and student athletes to enhance and create sustainable revenue flow for the student-athlete.

The American Association of Naturopathic Physicians to Celebrate Naturopathic Medicine Week, May 14-20

Retrieved on: 
Friday, May 12, 2023
NDS, INM, Herbal medicine, Molina Healthcare, Public policy, Naturopathy, National University of Natural Medicine, United States Senate, US, Patient, Nature, Physician, Health, AANP, Pharmaceutical industry

WASHINGTON, May 12, 2023 /PRNewswire-PRWeb/ -- Naturopathic Medicine Week, an annual event held to promote the benefits of naturopathic medicine, is set to take place from May 14 to May 20, 2023. The week-long event aims to showcase the value of naturopathic medicine to patients, prospective patients, public policy makers, reporters, and community leaders through various creative activities, events, and messages.

Key Points: 
  • WASHINGTON, May 12, 2023 /PRNewswire-PRWeb/ -- Naturopathic Medicine Week , an annual event held to promote the benefits of naturopathic medicine, is set to take place from May 14 to May 20, 2023.
  • The origins of Naturopathic Medicine Week date back to 2013 when the US Senate unanimously passed S. Res.
  • The practice of naturopathic medicine includes modern and traditional modalities, and encompasses a range of therapies, including botanical and herbal medicine, nutritional medicine, lifestyle counseling, naturopathic physical manipulation, and much more.
  • The AANP encourages everyone to participate in Naturopathic Medicine Week 2023 and learn more about the benefits of naturopathic medicine.

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, February 17, 2023
Loss, INMED, Toxicology, Cannabinoid, Investment, CBC, Patient, INM, Clinical trial, Research, GLP, Pharmacy, Glaucoma, Calendar, IND, MD, Pharmaceutical industry, Cryptocurrency, Security (finance), Epidermolysis bullosa

The Company’s full financial statements and related MD&A for the second quarter ended December 31, 2022, are available at www.inmedpharma.com , www.sedar.com and at www.sec.gov .

Key Points: 
  • The Company’s full financial statements and related MD&A for the second quarter ended December 31, 2022, are available at www.inmedpharma.com , www.sedar.com and at www.sec.gov .
  • As we move into calendar 2023, we have a strong pipeline of programs at various stages of development,” said Eric A. Adams, President and CEO of InMed.
  • “Fiscal Q2 saw significant cost savings across the different business segments resulting in a reduced cash burn.
  • BayMedica continues to be a leading producer of cannabichromene (CBC) with increased revenue in the last two quarters, including a 46% quarter over quarter increase in fiscal 2Q 2023.

InMed Submits Form 12b-25

Retrieved on: 
Friday, February 10, 2023
Pharmacy, INM, SEC filing, British Columbia Securities Commission, Requirement, Form, NP, Cannabinoid, National Policy

VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”).

Key Points: 
  • VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission (the “SEC”) in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”).
  • The Company intends to file a complete version of the Form 10-Q with the SEC, together with its corresponding quarterly filings in Canada (the “Required Filings”) within the five-day extension period afforded by Rule 12b-25 under the Securities Exchange Act of 1934, as amended.
  • The MCTO application has been made but there is no guarantee or assurance that the MCTO will be granted.
  • The Company anticipates that it will be in a position to remedy the default by filing the Required Filings on or about February 20, 2022.

InMed Provides Business Update and Milestones for 2023

Retrieved on: 
Tuesday, January 10, 2023
Database, Neurodegeneration, CBC, Molecule, Itch, THCV, Safety, Cannabinoid, FDA, Health, INMED, Glaucoma, BMI, Drug development, Radicle, CBDV, Patient, Appetite, CBT, Research, Clinical trial, Wound healing, Epidermolysis bullosa, Acquisition, INM, GLP, Pain, Pharmacy, Fine chemical, Pharmaceutical industry

Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s

Key Points: 
  • Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
    VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlines key accomplishments from 2022 and provides business update and catalysts for 2023.
  • Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed was able to advance its programs and achieve a number of key milestones.
  • As we move forward into 2023, we are very encouraged by the strength of our pharmaceutical programs, with several material milestones anticipated in the coming quarters,” commented Eric A. Adams, InMed President and CEO.
  • As we enter 2023, we will continue to evaluate strategic options and long-term supply agreements for this business segment.

InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor

Retrieved on: 
Monday, December 12, 2022
Audit committee, Internet, KPMG LLP, Pharmacy, University Avenue, Interim, Cyprus Securities and Exchange Commission, Circular, Security (finance), Letter, INM, Cannabinoid, Financial management, Suite, PST, Telephone, Exchange, Canada Business Corporations Act, SEDAR, KPMG, Proxy, Computershare, The Meeting, Research, National instrument, Form, Management, Accounting, INMED, Brio

Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.

Key Points: 
  • Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022.
  • The firm provides outsourced financial management and financial reporting support to small and middle market entities.
  • Marcum will stand for appointment at the Company’s Annual General Meeting, currently scheduled for Thursday, December 15, 2022 (the “Meeting”).
  • Eric A. Adams, Chief Executive Officer of InMed, commented, "We are delighted to engage Marcum as the Company’s new auditors.

InMed Pharmaceuticals Announces Closing of $6 Million Private Placement Priced at a Premium to Market

Retrieved on: 
Monday, November 21, 2022
Act, Exercise, Pharmacy, INM, Cannabinoid, Security (finance), Sale, Regulation D

The aggregate gross proceeds to the Company from the private placement were approximately $6 million.

Key Points: 
  • The aggregate gross proceeds to the Company from the private placement were approximately $6 million.
  • H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
  • In addition, preferred investment options to purchase up to an aggregate of 1,382,490 common shares of the Company which were previously issued to the investors in the private placement were cancelled.
  • We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada ("NSERC") Alliance Grant Funding

Retrieved on: 
Wednesday, November 16, 2022
Neurodegeneration, University of British Columbia, University, Glaucoma, Neuroprotection, UBC, Pharmacy, INM, Cannabinoid, Senior, Patent, INMED, Faculty, NSERC, Research, Neuron, Association of Medical / Pharmaceutical Sciences, Pharmaceutical industry

InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies.

Key Points: 
  • InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies.
  • In addition, Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner.
  • The funding will support the research and development studies of InMeds cannabinoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases.
  • Our team will continue this important research in neurodegenerative diseases under the NSERC Alliance grant.

InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update

Retrieved on: 
Friday, November 11, 2022
Health, Clinical trial, Research, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sale, FDA, Glaucoma, Drug discovery, Mission statement, Pressure, Company, Investment, Food, Pharmacy, MD, INM, Wound healing, CBN, Disease, Neurodegeneration, Calendar, Review, Person, Toxicology, GLOBE, Cannabinol, Acquisition, Patient, Enrollment, Dermatology, INMED, Safety, Epidermolysis bullosa, Cannabinoid, GLP, EB, Nasdaq, Neuroprotection, Pharmaceutical industry, Airline

VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 11, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.
  • The Companys condensed financial statements and related MD&A for the first quarter of fiscal year 2023, ended September 30, 2022 will be available at www.inmedpharma.com and at www.sedar.com .
  • Enrollment and patient treatment in the Companys Phase 2 clinical trial, 755-201-EB, has continued through the first quarter and is expected to complete during calendar year 2022.
  • InMeds Phase 2 clinical trial now has all 11 clinical trial sites fully activated to screen and enroll patients.